KR20250028537A - 암에 대한 조합 요법 - Google Patents

암에 대한 조합 요법 Download PDF

Info

Publication number
KR20250028537A
KR20250028537A KR1020257005808A KR20257005808A KR20250028537A KR 20250028537 A KR20250028537 A KR 20250028537A KR 1020257005808 A KR1020257005808 A KR 1020257005808A KR 20257005808 A KR20257005808 A KR 20257005808A KR 20250028537 A KR20250028537 A KR 20250028537A
Authority
KR
South Korea
Prior art keywords
ser
thr
leu
val
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257005808A
Other languages
English (en)
Korean (ko)
Inventor
킨-밍 로
옌 란
Original Assignee
메르크 파텐트 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 메르크 파텐트 게엠베하 filed Critical 메르크 파텐트 게엠베하
Publication of KR20250028537A publication Critical patent/KR20250028537A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N5/1077—Beam delivery systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1085—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy characterised by the type of particles applied to the patient
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020257005808A 2016-08-12 2017-08-11 암에 대한 조합 요법 Pending KR20250028537A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662374621P 2016-08-12 2016-08-12
US62/374,621 2016-08-12
KR1020237028359A KR20230125859A (ko) 2016-08-12 2017-08-11 암에 대한 조합 요법
PCT/EP2017/070513 WO2018029367A1 (en) 2016-08-12 2017-08-11 Combination therapy for cancer

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237028359A Division KR20230125859A (ko) 2016-08-12 2017-08-11 암에 대한 조합 요법

Publications (1)

Publication Number Publication Date
KR20250028537A true KR20250028537A (ko) 2025-02-28

Family

ID=59686928

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020237028359A Ceased KR20230125859A (ko) 2016-08-12 2017-08-11 암에 대한 조합 요법
KR1020197006703A Ceased KR20190039200A (ko) 2016-08-12 2017-08-11 암에 대한 조합 요법
KR1020257005808A Pending KR20250028537A (ko) 2016-08-12 2017-08-11 암에 대한 조합 요법

Family Applications Before (2)

Application Number Title Priority Date Filing Date
KR1020237028359A Ceased KR20230125859A (ko) 2016-08-12 2017-08-11 암에 대한 조합 요법
KR1020197006703A Ceased KR20190039200A (ko) 2016-08-12 2017-08-11 암에 대한 조합 요법

Country Status (16)

Country Link
US (2) US20180118832A1 (enExample)
EP (1) EP3497130B1 (enExample)
JP (1) JP7573365B2 (enExample)
KR (3) KR20230125859A (enExample)
CN (1) CN109641963A (enExample)
AU (2) AU2017310027A1 (enExample)
BR (1) BR112019001818A2 (enExample)
CA (1) CA3031168A1 (enExample)
CL (1) CL2019000277A1 (enExample)
ES (1) ES2905663T3 (enExample)
IL (1) IL264730B2 (enExample)
MX (1) MX2019001503A (enExample)
PH (1) PH12019500270A1 (enExample)
RU (1) RU2019106663A (enExample)
SG (1) SG11201901126UA (enExample)
WO (1) WO2018029367A1 (enExample)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1225740A1 (zh) 2013-08-22 2017-09-15 Acceleron Pharma Inc. TGF-β受体II型变体及其用途
CN116327952A (zh) 2015-08-04 2023-06-27 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
EP3628049B1 (en) 2017-05-04 2023-05-10 Acceleron Pharma Inc. Tgf-beta receptor type ii fusion proteins and uses thereof
AU2019238573A1 (en) * 2018-03-23 2020-10-01 The University Of Western Australia Method for immunotherapy drug treatment
WO2019211489A1 (en) * 2018-05-04 2019-11-07 Merck Patent Gmbh COMBINED INHIBITION OF PD-1/PD-L1, TGFβ AND DNA-PK FOR THE TREATMENT OF CANCER
KR20210009339A (ko) * 2018-05-15 2021-01-26 메르크 파텐트 게엠베하 치료 나이브 대상체의 암 치료에 사용하기 위한 표적화된 TGF-β 억제를 위한 투약 레지멘
MX2020013535A (es) * 2018-06-13 2021-02-26 Merck Patent Gmbh Tratamiento de cáncer pulmonar de células no pequeñas (nsclc) en etapa iii y mitigación de las condiciones patológicas asociadas con el tratamiento.
TW202019405A (zh) * 2018-07-02 2020-06-01 德商馬克專利公司 用於治療晚期非小細胞肺癌之標靶性TGF-β抑制之組合療法
CN120775065A (zh) * 2018-07-09 2025-10-14 普瑞赛格恩公司 融合构建体及其使用方法
TW202039558A (zh) * 2018-11-30 2020-11-01 大陸商江蘇恆瑞醫藥股份有限公司 抗ｃｄ４０抗體、其抗原結合片段及其醫藥用途
MX2021009175A (es) 2019-01-30 2021-09-14 Scholar Rock Inc Inhibidores especificos del complejo de ltbp de tgf? y usos de los mismos.
EP3693974A1 (en) * 2019-02-07 2020-08-12 Koninklijke Philips N.V. Identifying responsiveness to radio-immuno combination therapy
EP3929215A4 (en) * 2019-06-10 2022-06-22 Shandong Boan Biotechnology Co., Ltd. BIFUNCTIONAL FUSION PROTEIN AGAINST PDL1 AND TGF? AND ITS USE
EP3990116A1 (en) 2019-06-28 2022-05-04 Gensun Biopharma Inc. ANTITUMOR ANTAGONIST CONSISTING OF A MUTATED TGFß1 - RII EXTRACELLULAR DOMAIN AND AN IMMUNOGLOBULIN SCAFFOLD
CN112442132A (zh) * 2019-09-05 2021-03-05 复旦大学 靶向肿瘤的重组双功能融合蛋白及其应用
CA3151030A1 (en) * 2019-09-12 2021-04-01 David M. Evans Co-delivery of tgf-.beta. sirna and pdl1 sirna to treat cancer
CN112574314A (zh) * 2019-09-30 2021-03-30 和铂医药(苏州)有限公司 一种融合蛋白及其应用
EP4048704A4 (en) 2019-10-21 2023-11-22 Nanjing Leads Biolabs Co., Ltd. RECOMBINANT PROTEIN TARGETING PD-1 AND TGFß
IL292613A (en) * 2019-11-01 2022-07-01 Ares Trading Sa Combined inhibition of pd-1, tgfβ and atm together with radiotherapy for the treatment of cancer
CA3155219A1 (en) * 2019-11-05 2021-05-14 Merck Patent Gmbh Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer
EP4073124A4 (en) * 2019-12-11 2024-01-24 Wuxi Biologics Ireland Limited BIFUNCTIONAL ANTIBODY AGAINST PD-L1 AND TGFBETA
EP3838260A1 (en) 2019-12-20 2021-06-23 Ares Trading S.A. Igg:tgf rii fusion protein composition
KR20220118514A (ko) 2019-12-20 2022-08-25 아레스 트레이딩 에스.아. IgG:TGF베타RII 융합 단백질 조성물
TW202135862A (zh) 2020-01-11 2021-10-01 美商供石公司 TGFβ抑制劑及其用途
WO2021142448A2 (en) 2020-01-11 2021-07-15 Scholar Rock,Inc. Tgf-beta inhibitors and use thereof
CN115175942B (zh) * 2020-02-25 2025-05-30 上海药明生物技术有限公司 一种双功能融合蛋白及其用途
US20230149543A1 (en) * 2020-04-14 2023-05-18 Glaxosmithkline Intellectual Property Development Limited Combination treatment for cancer based upon an icos antbody and a pd-l1 antibody tgf-bets-receptor fusion protein
WO2021209458A1 (en) 2020-04-14 2021-10-21 Ares Trading S.A. Combination treatment of cancer
WO2022011256A1 (en) 2020-07-10 2022-01-13 Precigen, Inc. Fusion constructs and methods of using thereof
CN113968903A (zh) * 2020-07-24 2022-01-25 迈威(上海)生物科技股份有限公司 TGF-β RII突变体及其融合蛋白
WO2022063193A1 (zh) * 2020-09-24 2022-03-31 上海齐鲁制药研究中心有限公司 同时靶向PD-L1和TGFβ的双功能分子及其医药用途
JP2023553257A (ja) 2020-11-02 2023-12-21 アレス トレーディング ソシエテ アノニム がんの組み合わせ治療
JP2023550900A (ja) * 2020-11-02 2023-12-06 アレス トレーディング ソシエテ アノニム がんの組み合わせ治療
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
EP4333900A2 (en) 2021-05-03 2024-03-13 Merck Patent GmbH Her2 targeting fc antigen binding fragment-drug conjugates
WO2022248380A1 (en) 2021-05-25 2022-12-01 Merck Patent Gmbh Egfr targeting fc antigen binding fragment-drug conjugates
EP4348260A2 (en) 2021-06-03 2024-04-10 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
AU2022288571A1 (en) 2021-06-07 2024-01-04 Ares Trading S.A. Combination treatment of cancer
GB202215997D0 (en) * 2022-10-28 2022-12-14 Io Biotech Aps Therapy
KR20250133913A (ko) 2023-01-09 2025-09-09 베이징 투오 지에 바이오파마수티컬 컴퍼니 리미티드 TGFβ1 결합 분자, GARP-TGFβ1 결합 분자 및 이의 의학적 용도
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
RU2003129528A (ru) 2001-03-07 2005-04-10 Мерк Патент ГмбХ (DE) Способ экспрессии белков, содержащих в качестве компонента гибридный изотип антитела
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
RS54271B1 (sr) 2005-07-01 2016-02-29 E. R. Squibb & Sons, L.L.C. Humana monoklonska antitela za ligand programirane smrti 1 (pd-l1)
HRP20170908T1 (hr) 2008-12-09 2017-09-22 F. Hoffmann - La Roche Ag Protutijela anti-pd-l1 i njihova uporaba za poboljšanje funkcije t-stanice
RS61033B1 (sr) * 2011-11-28 2020-12-31 Merck Patent Gmbh Antitela na pd-l1 i njihova upotreba
ES2938182T3 (es) * 2012-04-30 2023-04-05 Biocon Ltd Proteínas de fusión dirigidas/inmunomoduladoras y métodos de preparación de las mismas
KR102129636B1 (ko) * 2012-05-31 2020-07-03 제넨테크, 인크. Pd-l1 축 결합 길항제 및 vegf 길항제를 사용하여 암을 치료하는 방법
AU2015213988B2 (en) * 2014-02-10 2019-07-11 Merck Patent Gmbh Targeted TGFbeta inhibition

Also Published As

Publication number Publication date
JP2019527706A (ja) 2019-10-03
KR20190039200A (ko) 2019-04-10
ES2905663T3 (es) 2022-04-11
EP3497130A1 (en) 2019-06-19
CA3031168A1 (en) 2018-02-15
AU2024219446A1 (en) 2024-09-26
IL264730B1 (en) 2024-05-01
MX2019001503A (es) 2019-06-03
SG11201901126UA (en) 2019-03-28
EP3497130B1 (en) 2021-10-27
US20220017621A1 (en) 2022-01-20
CN109641963A (zh) 2019-04-16
IL264730B2 (en) 2024-09-01
RU2019106663A3 (enExample) 2020-11-26
CL2019000277A1 (es) 2019-07-05
KR20230125859A (ko) 2023-08-29
AU2017310027A1 (en) 2019-01-31
RU2019106663A (ru) 2020-09-14
US20180118832A1 (en) 2018-05-03
JP7573365B2 (ja) 2024-10-25
PH12019500270A1 (en) 2019-07-01
WO2018029367A1 (en) 2018-02-15
IL264730A (en) 2019-03-31
BR112019001818A2 (pt) 2019-05-07

Similar Documents

Publication Publication Date Title
KR20250028537A (ko) 암에 대한 조합 요법
AU2019246876B2 (en) Targeted TGFß Inhibition
US20240018257A1 (en) Antibodies specific to human poliovirus receptor (pvr)
KR20190102059A (ko) 표적화된 TGF-β 억제를 위한 투약 레지멘 및 투여 형태
CN112566634A (zh) Iii期nsclc治疗和与治疗相关的病理状况缓解
CN112638374A (zh) 用于治疗晚期非小细胞肺癌的采用靶向的TGF-β抑制的组合疗法
KR20210009339A (ko) 치료 나이브 대상체의 암 치료에 사용하기 위한 표적화된 TGF-β 억제를 위한 투약 레지멘
CN115605268A (zh) 抗pd-1抗体及使用方法
KR20210022680A (ko) 담도암의 치료에 사용하기 위한 표적화된 TGF-β 억제를 위한 투약 레지멘
TW202146437A (zh) Ｃｄ８０胞外域ｆｃ融合蛋白療法
HK40064486A (en) TARGETED TGFβ INHIBITION
HK40050217A (en) Combination therapy with targeted tgf-b inhibition for treatment of advanced non-small cell lung cancer
HK40042110A (en) Dosing regimens for targeted tgf-b inhibition for use in treating cancer in treatment naive subjects
HK40005313A (en) Combination therapy for cancer
HK40049078A (en) Dosing regimens for targeted tgf-β inhibition for use in treating biliary tract cancer
HK40050239A (en) Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment
HK40012523A (en) DOSING REGIMENS AND DOSAGE FORMS FOR TARGETED TGF-β INHIBITION

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20250221

Application number text: 1020237028359

Filing date: 20230821

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20250321

Comment text: Request for Examination of Application